The Federal Trade Commission staff reviewing Roche’s plan to buy U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion recommended that the deal be approved without requiring any asset sales, the Capitol Forum reported on Thursday.
Basel-based Roche, the biggest maker of cancer drugs, said in February that it would buy the U.S. company, acquiring a portfolio that includes a blindness treatment that has U.S. and European approval and other projects for neurodegenerative disorders like Huntington’s disease. One of its projects is a gene therapy treatment for hemophilia.
The FTC staff had focused on hemophilia treatments since Roche markets Hemlibra, the report said.
Following the staff’s recommendation, officials at the top of the FTC’s Bureau of Competition must weigh in. The next step would be a vote by the FTC chairman and four commissioners.
The deal must also win approval from the UK’s Competition and Markets Authority, which said this week that it had a deadline of mid-December for a Phase 1 decision. A Phase 2 probe would be more in-depth and detailed.
Roche, Spark and the FTC all declined comment.
By Diane Bartz
Source: Reuters
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
